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ABSTRACT
Objectives: To understand the perspectives of stroke
survivors, caregivers and general practitioners (GPs)
on a polypill approach, consisting of blood pressure
and cholesterol-lowering therapies, with or without
aspirin, for the secondary prevention of stroke.
Methods: A qualitative interview study was undertaken
in 5 GP surgeries in the East of England. 28 survivors
of stroke/transient ischaemic attack (TIA) were
interviewed, 14 of them with a caregiver present, along
with a convenience sample of 5 GPs, to assess
attitudes towards a polypill and future use. Topic
guides explored participants attitudes, potential uptake
and long-term use, management of polypill medication
and factors influencing the decision to prescribe. Data
were analysed using a grounded theory approach. Key
themes are presented and illustrated with verbatim
quotes.
Results: The analysis identified 3 key themes: polypill
benefits, polypill concerns and polypill lessons for
implementation. Stroke/TIA survivors were positive
about the polypill concept and considered it acceptable
in the secondary prevention of stroke. Perceived
benefits of a polypill included convenience resulting in
improved adherence and reduced burden of treatment.
Caregivers felt that a polypill would improve
medication-taking practices, and GPs were open to
prescribing it to those at increased cardiovascular risk.
However, concerns raised included whether a polypill
provided equivalent therapeutic benefit, side effects
through combining medications, consequences of non-
adherence, lack of flexibility in regulating dosage,
disruption to current treatment and suitability to the
wider stroke population.
Conclusions: Participants acknowledged potential
advantages in a polypill approach for secondary
prevention of stroke; however, significant concerns
remain. Further research on the efficacy of a polypill is
needed to reassure practitioners whose concerns
around inflexibility and treatment suitability are likely to
influence the decision to prescribe a polypill for
secondary prevention of stroke. Acceptability among
survivors, caregivers and GPs is likely to determine
the uptake and subsequent use of a polypill in the
future.
INTRODUCTION
Stroke is the fourth most common cause of
death in the UK, responsible for ∼40 000
deaths every year1 and is also a signiﬁcant
cause of acquired adult disability,2 with about
half of all survivors experiencing some
degree of physical or cognitive impairment3
and left dependent on others.4
People who have had a stroke or a transi-
ent ischaemic attack (TIA; also known as a
ministroke) are at higher long-term risk and
therefore exposed to the increased possibility
of having a further event.5 6 However, this
risk can be substantially reduced through the
use of preventative medications such as anti-
platelet agents7 or anticoagulants,8 as well as
cholesterol-lowering9 10 and blood pressure
(BP)-lowering therapies.11
Despite evidence-based guidelines, treat-
ment for stroke often falls below recom-
mended standards,12 13 and signiﬁcant
Strengths and limitations of this study
▪ This research adds to an important body of work
exploring cardiovascular polypills and is the first
study to focus on attitudes to a polypill for
secondary prevention of stroke.
▪ The findings are strengthened by the inclusion of
caregivers who have an important role to play in
managing the medication of stroke/transient
ischaemic attack survivors.
▪ Conducting a qualitative assessment of individual
perspectives allowed an in-depth examination of
the subject area.
▪ Owing to the limited sample size, findings may
not generalise to the wider stroke population or
necessarily represent the views of all general
practitioners.
▪ Future research should consider harder to reach
groups such as those who need support to
manage medication and may benefit most from a
polypill approach.
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deﬁciencies in secondary prevention care have been
reported.14 The use of multiple medications to treat
cardiovascular disease (CVD) is often associated with
inappropriate medication use (eg, underuse, or use of
non-appropriate medicines), underprescription and
reduced adherence.15 A polypill consisting of cholesterol-
lowering and BP-lowering therapies, with or without
aspirin in a single pill for the treatment of CVD16 has
been proposed.
Wald and Law17 introduced the polypill concept and
estimated a theoretical 88% reduction in ischaemic
heart disease and 80% reduction in stroke, if taken by
everyone over 55 years. Since then a growing body of lit-
erature has developed around a polypill, otherwise
known as a ﬁxed-dose combination (FDC) pill, for the
prevention of CVD.18 19 A series of recently completed
trials investigating the role of a FDC pill on adherence
to medication for secondary prevention demonstrated
improved adherence for the polypill strategy compared
with standard care.20–22 Elsewhere, FOCUS found
improved adherence for patients with myocardial infarc-
tion in the polypill group compared with the group
given the three drugs separately.23
To date, a small number of studies have investigated
the perspectives of patients and healthcare professionals
towards a theoretical polypill. Although cardiovascular
patients considered it convenient, they had concerns
around the inﬂexibility of a polypill24; however, general
practitioners (GPs) would consider prescribing it to
those who needed secondary prevention medication if it
was shown to be effective.25–28 With adherence to medi-
cation in stroke survivors known to be suboptimal,29 this
group may be particularly suited to treatment with an
FDC polypill.
The aim of this study was to explore the attitudes and
perspectives of stroke/TIA survivors, carers and GPs
towards a polypill approach for the secondary preven-
tion of stroke, including the beneﬁts and consequences
of using a polypill, factors likely to inﬂuence uptake,
the caregiver role in managing medication, and GPs’
views and attitudes towards prescribing a polypill in
the future.
METHODS
Study design and participants
A qualitative study using semistructured interviews was
undertaken. The stroke registers of ﬁve GP practices in
the East of England were searched. The criteria for
inclusion of stroke survivors was being over the age of
55 years, with a diagnosis of stroke or TIA and able to
speak English. Based on these criteria, a list of prospect-
ive participants was generated by the practice administra-
tor. The list was then screened by the practice GP and
anyone deemed unsuitable, such as those unable to
provide informed consent or who were terminally or ser-
iously ill, was removed. Purposive sampling was used to
recruit stroke/TIA survivors with maximum variation
characteristics representing a spread of socioeconomic
status,30 age, gender and disability.31 Survivors were sent
a study information pack and invited to interview.
Caregivers were approached by the stroke survivor with a
study information pack and invited to participate. All
caregivers were subsequently interviewed in the presence
of a stroke survivor. Owing to time constraints, we chose
not to interview caregivers separately. All interviews were
conducted in the stroke survivors’ homes. We also
sought the views of a convenience sample of GPs, each
of whom was the study lead for their practice. The GP
was contacted by phone and an interview arranged at
their place of work. The number of interviews con-
ducted was determined by data saturation, the point
where no new information emerged from discussions.
Interviews were face to face and consent was taken in
person before any discussion started.
Data collection
Data were collected through semistructured interviews
with open-ended questions that deﬁned the area to be
explored.32 Topic guides were developed by the authors
and informed by current literature in the ﬁeld and
expertise within the study team which included a GP, a
qualitative researcher and a stroke expert. To ensure
ease of understanding and suitability, topic guides were
piloted with two stroke survivors and checked by a GP.
Any appropriate recommendations were considered and
implemented. Data from the two pilot interviews was
included in the ﬁnal analysis. All interviews were con-
ducted by the lead author (JJ) who has considerable
experience in qualitative research analysis. Field notes
were also taken by the interviewer. Topics discussed were
perceived beneﬁts and consequences of a polypill,
factors inﬂuencing polypill uptake, caregiver views, and
GPs’ beliefs and attitudes towards prescribing a polypill
(see online supplementary ﬁle 1 for the interview sched-
ule). The schedule of questions was reﬁned and ﬁna-
lised after the ﬁfth interview to include questions on the
wider experience of stroke as well as understanding of
the polypill approach and the GP relationship.
Interviews were audiotaped, lasted 1–1.5 h and were
transcribed verbatim.
Data analysis
We followed the Strauss and Corbin Grounded Theory
approach using constant comparative analysis.33 This
method permits key points to emerge from the data and
to then be coded individually. A set of codes, represent-
ing initial themes, were developed from chunks of data.
Codes were then further reﬁned, and those representing
similar concepts were grouped together to form categor-
ies. The identiﬁcation and reﬁnement of categories con-
tinued until the ﬁnal themes emerged. Nvivo V.9 (QSR
Intl, Melbourne, Victoria, Australia) was used to organ-
ise, code and manage the data. Transcripts were entered
into the program and coded by JJ, with 20% double
coded independently by SS. Queries arising from coded
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transcripts were settled through discussion.
Communication with a third author ( JG) enabled clariﬁ-
cation and reﬁnement of categories until a consensus
was reached.
RESULTS
A total of 28 stroke/TIA survivors participated. Fourteen
were interviewed alone and 14 with the caregiver
present, who was either a spouse (n=12) or family
member (n=2). Characteristics of survivors are displayed
in table 1. Three male GPs and two female GPs were
also interviewed. One GP was white British, one was
Chinese and three were of south Asian origin. Key
themes identiﬁed reﬂected the positive and negative
aspects of the polypill approach as well as future use.
Subthemes highlighted beneﬁts and concerns associated
with a polypill approach and factors likely to inﬂuence
stroke survivors using a polypill.
Polypill benefits
The concept of a polypill was broadly acceptable to sur-
vivors and caregivers. Greater convenience leading to
better adherence, conﬁdence that a polypill was provid-
ing the appropriate treatment, reduced treatment
burden, ease of use and improved medication manage-
ment were all considered beneﬁts. For GPs, a polypill
facilitated medication taking and provided ﬂexibility in
treatment and convenience around prescribing
practices.
Convenience
Survivors were enthusiastic about one tablet combining
all stroke medication and reducing treatment burden
through minimising the inconvenience of managing
multiple medications.
That is the best thing I’ve read when it said you might
have to take one pill to cover the lot. Super, because that
is just a bugbear, it’s a bugbear in life. (p. 11, Male,
73 years)
A single tablet was considered easier to remember and
likely to improve overall medication-taking behaviour.
I think it’s brilliant because erm I, I’ve got more chance
of remembering to take one tablet than I have of remem-
bering two different times of the day if you like. (p. 10,
Male, 66 years)
Caregivers also endorsed the view that a polypill
improved compliance and that it ensured the appropri-
ate medications were being taken.
It means that if you’ve taken that one you’ve taken them
all. Whereas sometimes if you run short, you think oh I’ll
just take that one and forget about the other one until you
go to the doctors and get the reﬁll. (p. 02, Female, carer)
GPs also felt that a polypill had the potential to
improve medication adherence.
I think that would reduce the pill burden to our patients
and I think that’s very good idea…I think he would be
very compliant with it, because he is thinking that he is
going to be taking 1 tablet and not 5 tablets…(GP 02,
Female)
The potential for ‘cross-over’ treatment in individuals
with multiple existing cardiovascular comorbidities was
mentioned.
If you’re giving polypill in the form of one pill, even with
people with comorbidities (you’re) maybe reducing their
number…and might improve overall compliance and it
may have the side effect of improving their comorbidity
as well. (GP 05, Male)
For carers, the polypill approach made the
medication-taking process less demanding.
It’s logic to me and I think it’s an excellent idea if it could
be done, certainly instead of [patient] ﬁddling about in a
saucer trying to pick up tablets. (p. 28, Male, carer)
They also felt that the process of managing medica-
tion was better, compared with using multiple
medications.
Table 1 Stroke survivor characteristics
Gender Male: n=21 (75%)
Female: n=7 (25%)
Age (mean:
74 years)
60–69 years: n=10 (36%)
70–79 years: n=11 (39%)
80–89 years: n=7 (25%)
Ethnicity White: n=27 (97%),
South Asian: n=1 (3%)
Stroke
classification
Stroke: n=14 (50%)
TIA: n=14 (50%)
Time since stroke 6 months to 2 years; n=10 (35%)
3–5 years: n=8 (29%)
6–10 years: n=5 (18%)
>10 years: n=5 (18%)
Diabetes status Yes: n=9 (32%)
No: n=19 (68%)
Smoking status Non-smoker: n=15 (54%)
Ex-smoker: n=11 (39%)
Smoker: n=2 (7%)
Interview status Survivor and caregiver: n=14 (50%)
Survivor only: n=14 (50%)
Rankin score*
MrS-9Q
No symptoms: (0) n=6 (21%)
No significant disability: (1) n=4 (14%)
Slight disability: (2) n=6 (21%)
Moderate disability: (3) n=4 (14%)
Mod severe/severe disability: (4–5)
n=8 (29%)
*Rankin score is derived from a scale that measures the degree of
disability in the daily activities of people who may have suffered a
stroke.
MrS-9Q, Modified Rankin Scale; TIA, transient ischaemic attack.
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Well if it’s only one tablet a day it would be quicker,
wouldn’t it? for a start. I mean I usually sit on a night-
time and do that (pillbox) when I’m watching telly.
There’s a few times I’ve missed out the odd tablet or put
a double in or put too many in so I mean that would be
easier. (p. 02, Female, carer)
Benefits of correct treatment
A polypill offered the beneﬁt of correct medication and
it ensured that the patient received their recommended
medications.
It could protect, once you had polypills that contained a
mixture of medications which are known not to have…
contradictory side-effects…then you would feel very safe.
(p. 03, Male, 86 years)
And as long as it’s whether it’s one pill or four pills so
you know this is my point of view I don’t think it’s going
to affect I mean other people might oh yeah I could
have four pills instead of one and they’ll start worrying
about it but no I erm I just accept that, that the people
are doing their job properly and getting their facts
right…as I say as long as the scientists have got it alright
you know you’ve got to have faith in them. (p. 08, Male,
87 years)
There was also conﬁdence that components were safe,
tested and therefore provided the most appropriate
treatment.
I’m all for these things…it might not be good for you, It
might not, I don’t know I can’t see how because if
they’re now gonna put four different pills into one they
musta investigated a, b, c and d to put them in one so
therefore it’s going to be beneﬁcial to me and anybody
else that wants those four in one. (p. 11, Male, 73 years)
Polypill concerns
Survivors’ and caregivers’ concerns included polypill
non-compliance resulting in missing all medications,
inability to adjust dosage, whether a polypill could main-
tain the beneﬁts of the survivors’ current secondary pre-
vention medication, timing of a polypill, identifying the
source of polypill side effects and modifying treatment if
a component was no longer required. GPs questioned
whether a single pill could treat the entire stroke popula-
tion, the cost implications of treatment and the wisdom
in modifying a patient’s stable treatment regimen.
Appropriateness of treatment
Several survivors expressed concern that a polypill may
not sustain equivalent therapeutic beneﬁt of secondary
prevention treatment.
As far as I’m concerned you’ve got one tablet with all the
ingredients of the others…if I’ve got the same erm
dosage of statin and if it didn’t disturb my readings then
yeah I mean erm what are the objections to it? (p. 05,
Male, 64 years)
Others also had concerns about the prospect of a ‘pill
for all’, inability to alter dosage and being less amenable
to dose titration, if that was required.
Would the polypill be in different strengths because like
for blood pressure at the moment I’m taking…12 and a
half, and then me cl- clopridogrel is 75…maybe six
months down the line my blood pressure can reduce, what
would that do with the polypill? (p. 21, Female, 68 years)
Survivors accustomed to scheduled medication regi-
mens also questioned how drugs could now be com-
bined and taken at a single time point.
if you’ve got them altogether and you’re supposed to
take those tablets at different times of the day, how’s it
going to work? Is it going to upset your system? (p. 22,
Female, 71 years)
Suitability of the polypill strategy
Survivors questioned the ease of managing treatment if
one or more components were no longer required.
Would it only be suitable for somebody who’s taking four
of that particular medication? But what would happen if
say the Dr said, you’re not so bad so you don’t need to
take that particular tablet? (p. 16, Female, 82 years)
A few expressed concerns around the inclusion of
statins in any combination pill.
Yes has that got anything to do with statins? I’ve read a lot
about statins and I’m afraid I feel I wouldn’t want to take
them. Because the side effects and everything. (p. 19,
Female, carer)
GPs were cautious, suggesting a polypill could be
better suited to those on similar medications whose
treatment was well established.
I think the right drugs in the right combinations there,
it, would potentially be helpful for a cohort of people. I
don’t think it will be for everyone but there will be a
cohort of people who will probably be on very similar
drugs…(GP03, Male)
Survivors and carers were also concerned that poor
adherence would lead to missing all their secondary pre-
vention drugs.
If you’re gonna give them a polypill that is three or four
tablets and they don’t bother taking that…They’re gonna
be worse off. (p. 14, Male, carer)
Given the unique needs of stroke survivors, some sug-
gested that multiple polypills may be needed.
They don’t give me three separate ones for no reason,
there must be a reason for it. You can’t do that with a
polypill unless you have a hundred polypills all different
medications and different combinations. (p. 18, Male,
88 years)
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Polypill side effects
The likelihood of polypill side effects led many to ques-
tion the suitability of single pill treatment.
The ﬁne tuning takes a bit of doing so w- with the one
pill I got my bit of a doubt that it might work for some
people but it might not work for everybody you see.
(p. 04, Male, 80 years)
For GPs, a further problem resulting from this was the
potential difﬁculty in identifying the component of a
polypill responsible for side effects.
My personal anxiety is about side effects when you
club two, three medicines together, if one of them, one
of the components is, is causing the side effect then
you’ll not know, you may have to again change. (GP 05,
Male)
Medication adjustment
GPs questioned the beneﬁt in altering established
medication routines to accommodate a polypill in
those who were already taking their medication as
directed.
If you’ve got, as I said, a very motivated patient they
are happy with what they are taking, then we don’t prob-
ably have to intervene, but we may have to give to
people who are not that motivated or compliant.
(GP 05, Male)
They also expressed concern about the inconvenience
of having to readjust future treatment if polypill compo-
nents were no longer required.
If somebody has a problem ok well we’ll just stop using
the polypill and give them the individual ones but with
that stopping and chopping and changing people will say
they’ve changed my tablets again, that becomes an issue.
(GP 04, Male)
However, inﬂexibility of a polypill and the inability to
manipulate dosage was perhaps the greatest concern
among GPs.
We do switch around quite a bit different brands, differ-
ent sizes, statins and sometimes it may not be the right
dose but you kind of slowly edge it in…It would be
advantageous if it was a single pill but that would be
maybe a bit difﬁcult with polypill…It’s the ﬁne tuning
that’s difﬁcult. (GP 01, Female)
Caregivers also expressed concern around the inﬂex-
ibility of a polypill and the potential difﬁculties in adjust-
ing dosage.
You would have to get the right strengths of each tablet.
“Where you were on atenolol 50 you are now on 25”.
Sometimes they change the strength of the tablet. That’s
where it would be harder to change with the polypill.
(p. 25, Female, carer)
Size of polypill
GPs raised concerns that a large pill could actually dis-
courage medication taking.
Yeah is it a horse tablet?…that’s going to have the other,
the opposite effect on compliance that we want…People
are going to start breaking it having half now and half
twelve hours later. (GP 03, Male)
The size was also highlighted by caregivers who
expressed concerns around a prospective polypill being
very large.
Not going to be horse pills are they…as we call them,
500 mg. (p. 07, Female, carer)
For some stroke survivors, a single pill was considered
much easier given the potential problems associated
with multiple medications which could be larger and
more difﬁcult to swallow.
If you can get it into one, it’s so much better, you haven’t
got to put all these tablets down your throat. I mean like
this might get stuck, and one of my tablets, if it gets stuck
it burns my throat so much so the other week I lost my
voice. (p. 06, Male, 61 years)
Cost of polypill
The burden of the polypill on National Health Service
(NHS) resources was also raised with a number of GPs
suggesting that a more expensive pill could be difﬁcult
to prescribe.
If it is cheaper then there won’t be an issue at all. if it
comes out to be more expensive than the four tablets
which you are giving individually to the patient then it
comes to be an issue. (GP 02, Female)
Cost implications for practices and pharmacies dis-
pensing a polypill were also considered with GPs
acknowledging the likelihood of reduced revenues asso-
ciated with a single pill.
They get an item fee for each thing they prescribe so if
you have 4 drugs you get a fee for each, if you put it in 1
pill that will account for one. (GP 04, Male)
Polypill lessons for implementation
Survivors thought that whether they used a polypill in
the future would depend on their doctor’s recommenda-
tion, but they also questioned the need for a polypill
given their satisfaction with current treatment. GPs
acknowledged that their support was likely to be inﬂuen-
tial in the decision to use a polypill and believed the
approach should be adopted if it was found to be beneﬁ-
cial to the patient. While stroke/TIA survivors were gen-
erally positive about the polypill approach, many were
non-committal on its future use, largely due to the lack
of existing evidence.
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Polypill recommendation
Caregivers felt that whether they used a polypill in the
future was likely to depend on their doctor recommend-
ing the treatment.
It sounds good but w- we’ve got to, we would have to
weigh up, listen to what the doctors say and the consul-
tants and see what history, because this polypill, from
what we’ve hear. Very, very little, it’s quite new, that’s all
we know. (p. 22, Male, carer)
While GPs felt comfortable with the polypill approach,
there was a preference for recommending a polypill to
those who were already using the medication
components.
I don’t think I’d be comfortable saying here’s a new
stroke patient, just start them with a polypill as a starting
point, I think I’d feel uncomfortable with that.
If I had patients that are on the four drugs that are in
there erm I think I’d probably feel fairly comfortable
saying well here’s one tablet that’s got all of those things
you’re on already. (GP 04, Male)
Satisfied with current medication
Being content with their current medication also made
survivors less enthusiastic about taking a polypill which
may have unwanted side effects.
Why take a tablet that perhaps will affect you. Plus the
fact I’m perfectly happy with what I’m on, you know, at
the moment anyway. Perhaps if I go a bit doo-lally or you
know erm…I would consider it. (p. 01, Female, 71 years)
While a concern raised among some study participants
was that there was as yet little scientiﬁc evidence in
support of a polypill approach.
No, I don’t think I’d like to be a guinea pig with it
though…I don’t know, I think I would rather continue
with what I’ve got until it’s absolutely perfected the poly-
pill. Get somebody else. (p. 23, Female, 74 years)
Endorsement of the polypill
GPs agreed that if they endorsed polypill, stroke/TIA
survivors were likely to accept it as a treatment for sec-
ondary stroke and commit to using it in the future.
I think the majority of our current patients if we told
them we think this is the right thing to do would prob-
ably be happy with that. It’s a fairly easy argument.
(GP 03, Male)
Furthermore, there was an obligation to try new and
innovative treatments like the polypill, if its potential
beneﬁts were proven.
I welcome change and innovation I’m excited by it…you
don’t know until you’ve tried it…We have to try it if there
was a potential beneﬁt there for people. (GP04, Male)
DISCUSSION
Summary of main findings
Stroke/TIA survivors and caregivers felt a polypill
offered greater convenience, reduced the burden of
treatment and improved adherence to medication. A
polypill also ensured that patients received the correct
treatment and that medications were safe. However, sur-
vivors expressed signiﬁcant concerns around the suitabi-
lity of a polypill if not already using its individual
components, the size of a polypill and the implication
for using a polypill if any component was no longer
needed. Other important limitations identiﬁed by parti-
cipants included the potential for side effects and the
inﬂexibility of the single pill approach. GPs felt that a
more expensive pill would be problematic and acknowl-
edged that their endorsement was key to it being
accepted. For survivors, the decision to use a polypill
would depend on the GP’s recommendation, but those
who were satisﬁed with their current treatment regimen
felt less inclined to change to a polypill.
Strengths and limitations
A strength of this study is that it adds to a growing and
important body of research on attitudes towards a car-
diovascular polypill with a focus on secondary preven-
tion of stroke. Second, the use of semistructured
interviews enabled an in-depth assessment of individual
perspectives. A further strength is the inclusion of care-
givers, who can make a signiﬁcant contribution in the
future management of polypill treatment. We believe
that being interviewed by a qualitative researcher rather
than a healthcare professional encouraged survivors to
be more open and to engage in discussion.
However, limitations include a relatively small sample
of GPs recruited from ﬁve general practice surgeries.
Although every effort was made to recruit a representa-
tive sample with varied disability, most survivors who
responded to our request to participate were primarily
able bodied with no signiﬁcant stroke symptoms and
independently managed their own medication. In addi-
tion, survivors were almost exclusively white British. With
some ethnic groups, particularly south Asians, known to
be at considerably higher risk of CVD,34 the study may
have beneﬁted from the including individuals who are
considered to be at a greater risk from stroke and likely
to be prospective users of polypill therapy. As a result,
survivors in our study may not represent the wider stroke
population. Furthermore, only ﬁve GPs were inter-
viewed, and their opinions may not reﬂect those of the
GP population at large. With all caregivers interviewed
in the presence of a survivor, this may have contributed
to individuals responding in a socially desirable manner
and understating their true views on secondary
prevention and the polypill. Investigating a polypill
among survivors with signiﬁcant symptoms and
dependent on others to organise their tablets may be an
area for future research in the ﬁeld. Finally, future
research should aim to include those harder to reach
6 Jamison J, et al. BMJ Open 2016;6:e010458. doi:10.1136/bmjopen-2015-010458
Open Access
group.bmj.com on July 11, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
groups of survivors who may beneﬁt most from a polypill
approach.
Comparisons with existing literature
The inﬂexibility of treatment and the potential for side
effects were considered key challenges of a polypill
approach. Concerns about side effects have previously
been identiﬁed as inﬂuencing medication-taking behavi-
our35 and recognised as a signiﬁcant barrier to adher-
ence in CVD medication.36 Our ﬁndings are also in line
with a recent UK primary care investigation in which
patients considered a secondary prevention polypill
acceptable, but were concerned about components
interacting and inﬂexibility of treatment.37 The inability
to adapt polypill dosage and the suitability of ﬁxed dose
treatment was a key concern for GPs in our study and
has been previously reported in studies exploring poly-
pill attitudes among GPs elsewhere. A small survey of 17
practitioners in New Zealand reported that having no
choice of polypill components or doses was the thing
GPs disliked most about the concept of a polypill.25 In
another UK study of primary healthcare professionals,
inability to titrate dosage was considered a major disad-
vantage of the polypill.28
The GPs in our study agreed that cost was a potential
impediment to prescribing a polypill in the future.
Compared with free combination medications, FDC
therapy has the potential to be relatively inexpensive
due to cheaper drug costs and reduced monitoring,38
and there is increasing evidence in the literature sup-
porting the cost-effectiveness of a polypill strategy.39 40
With modest costs considered a cornerstone of combin-
ation therapy,41 evaluations of the cost-effectiveness of
using polypills is urgently needed.
Improved adherence was recognised as a key advan-
tage of a polypill, and survivors acknowledged that a
single medication episode was easier to remember. With
frequent dosing regimens42 and polypharmacy asso-
ciated with poor patient compliance to cardiovascular
medications,43 44 a polypill approach offering a simpli-
ﬁed medication regimen has the potential to improve
adherence in the treatment of CVD.24 45 Our study cor-
roborates observations from a patient perspective on
whether a polypill could improve adherence, which
highlighted concerns around the efﬁcacy of a polypill
compared with current medications and the potential
for side effects.24
For caregivers, beneﬁts of a polypill included simplify-
ing the medication-taking process and ease in organising
pill boxes. In a recent study on factors that inﬂuenced
caregiving and medication management, participants
recognised complex medication needs as an impedi-
ment to care by increasing the demands placed on the
caregiver.46 Caregivers in our study recognised that a
polypill approach was potentially more convenient for
the pharmacy, an observation which has been conﬁrmed
in a recent qualitative investigation exploring pharma-
cists’ views towards a cardiovascular polypill.47
Stroke/TIA survivors expressed a reluctance to adopt
a future polypill strategy, citing GP approval as a key
factor. This not only supports the view that cardiovascu-
lar patients were inclined to do what their GPs told
them48 but also highlights the key role GPs can play in
promoting a polypill approach. Exploring the perspec-
tives of those with direct experience of the polypill can
contribute to the wider acceptability of a polypill strategy
and should continue to be a priority of future research.
While a polypill was acceptable to most patients of the
UMPIRE trial, some felt that FDC therapy was less tai-
lored to individual patient needs.49 A recent investiga-
tion of the views of cardiovascular patients and providers
who participated in polypill trials reported similar advan-
tages and concerns to those identiﬁed in our study,50
suggesting that polypill perspectives translate to other
regions and healthcare settings.
With research suggesting that health practitioners
often fail to fully explain the important elements of
medication when ﬁrst prescribing treatment,51 uptake of
a polypill may depend not only on the GP prescribing
therapy but also on informing and encouraging accept-
ance of the approach among stroke/TIA survivors and
their caregivers.
Implications for clinical practice
This study identiﬁed some positive aspects of a cardiovas-
cular polypill for the secondary prevention of stroke.
However, greater efforts are needed within the clinical
practice setting to reassure patients of the beneﬁts of a
polypill. Health professionals’ endorsement when pre-
scribing a polypill could also lead to greater acceptance
of this treatment approach and its use among stroke sur-
vivors, particularly as inadequate information and difﬁ-
culties with new medications are associated with poor
adherence.52 Further studies are needed with a broader
sample of GPs to corroborate the ﬁndings reported
here. With adherence among stroke survivors known to
be suboptimal,29 this patient group may be particularly
suited to receiving treatment using FDC polypill therapy.
Further research on the efﬁcacy of a polypill will also
reassure practitioners whose concerns around inﬂexibil-
ity and the suitability of treatment are likely to inﬂuence
the decision to prescribe a polypill to stroke/TIA
survivors.
CONCLUSION
A growing body of evidence suggests that a FDC pill may
have a role to play in the prevention of CVD. This study
contributes to the growing literature on cardiovascular
polypills, offers a unique insight into the ﬁeld of stroke,
and may inform future research and clinical practice on
secondary prevention in the UK. A polypill may also
have a role to play in improving adherence among
stroke survivors. The ﬁndings have informed the devel-
opment of PROPS—Preventative Role of a FDC Pill in
Stroke—a multicentre, open-label, randomised
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controlled trial of a FDC pill versus standard care for
secondary prevention of stroke in a primary care setting
(EudraCT number: 201300472229). However, addressing
patients’ and practitioners’ concerns and intensifying
efforts to increase the acceptability of this treatment
approach is likely to determine future use of a cardiovas-
cular polypill for the secondary prevention of stroke.
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